Summary
Signal counts
Assets tracked: 3
Watchlist assets: 2
Registry stop assets: 0
Sponsor overview
BeiGene
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT05609370 | https://clinicaltrials.gov/study/NCT03427814 | https://clinicaltrials.gov/study/NCT03736889
Assets
Linked programs
- Alcestobart: Watchlist Signal (2/5)
- Pamiparib: Low Signal (0/5)
- Tislelizumab (BGB-A317): Watchlist Signal (2/5)